Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
暂无分享,去创建一个
Alexandre Mamedov | Liying Zhang | L. Klotz | A. Loblaw | R. Nam | Laurence Klotz | Liying Zhang | Robert Nam | Adam Lam | A. Mamedov | Andrew Loblaw | Adam Lam
[1] J H Wasson,et al. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. , 1993, Archives of family medicine.
[2] L. Klotz. Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Ali,et al. PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .
[4] E. Metter,et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience , 2007 .
[5] Liying Zhang,et al. Modeling prostate specific antigen kinetics in patients on active surveillance. , 2006, The Journal of urology.
[6] J. Johansson,et al. Expectant management of early stage prostatic cancer: Swedish experience. , 1994, The Journal of urology.
[7] J. Hugosson,et al. Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174)) , 2007 .
[8] B. Hølund. Latent prostatic cancer in a consecutive autopsy series. , 1980, Scandinavian journal of urology and nephrology.
[9] T. Tammela,et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.
[10] Paul W Dickman,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[11] M. Barry,et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.
[12] Adam S. Kibel,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .
[13] M. Remzi,et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. , 2005, The Journal of urology.
[14] Steve Williams,et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience , 2007, BJU international.
[15] Neil Fleshner,et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.
[16] L. M. Franks,et al. Etiology, epidemiology, and pathology of prostatic cancer , 1973 .
[17] Alan Horwich,et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. , 2008, European urology.
[18] L. M. Franks. Proceedings: Etiology, epidemiology, and pathology of prostatic cancer. , 1973, Cancer.